期刊
MOLECULAR PHARMACEUTICS
卷 13, 期 7, 页码 2484-2491出版社
AMER CHEMICAL SOC
DOI: 10.1021/acs.molpharmaceut.6b00217
关键词
brain uptake; pharmacokinetics; prodrug transporter; perforin inhibitor
资金
- Academy of Finland [256837]
- Emil Aaltonen Foundation
- Finnish MS Foundation
- Sigrid Juselius Foundation
- Orion-Farmos Research Foundation
- Jenny and Antti Wihuri Foundation
- Academy of Finland (AKA) [256837, 256837] Funding Source: Academy of Finland (AKA)
We have recently reported that by converting a perforin inhibitor into an L-type amino acid transporter 1 (LAT1)-utilizing prodrug its cellular uptake can be greatly increased. The aim of the present study was to determine the in vivo and brain pharmacokinetics of two perforin inhibitors and their LAT1-utilizing prodrugs 1 and 2. In addition, the brain uptake mechanism and entry into primary mouse cortical neurons and astrocytes were evaluated. After 23 mu mol/kg i.p. bolus injection, the prodrugs' unbound area under the concentration curve in brain was 0.3 nmol/g x min, whereas the parent drugs could not reach the brain. The unbound brain concentrations of the prodrugs after 100 mu M in situ mouse brain perfusion were 521.4 +/- 46.9 and 126.9 +/- 19.9 pmol/g for prodrugs 1 and 2, respectively. The combination of competing transporter substrates for LAT1, L-tryptophan, and for organic anion transporting polypeptides, probenecid, decreased the brain concentrations to 352.4 +/- 44.5 and 70.9 +/- 7.0 pmol/g, respectively. In addition, in vitro uptake studies showed that at 100 mu M prodrug 1 had 3.4-fold and 4.5-fold higher uptake rate into neurons and astrocytes, respectively, compared to its parent drug. Thus, the prodrugs enhance significantly the therapeutic potential of the parent drugs for the treatment of disorders of central nervous system in which neuroinflammation is involved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据